Title of Invention

PROCESS FOR POTENTIATING THERAPEUTIC HERBAL POWDERS FOR PREPARATION OF POTENT PHARMACEUTICAL COMPOSITIONS

Abstract The invention discloses a process of potentiating therapeutic powder of herb/herbs by adding beneficial extractives either individually or in combination containing all the temperature sensitive lypophylic active ingredients thereof and which are free from toxic solvent residues, slightly polar and water-soluble extractives. The invention further discloses novel compositions comprising the potentiated therapeutic powder of herb/herbs comprising beneficial extractives of herb / herbs and raw powder of herb/ herbs thereby obviate the need of inactive carriers. The invention also discloses process of combining beneficial extractives from the selected herbs preferably comprising all the temperature sensitive lypophylic active ingredients, slightly polar and water soluble extractives which are free from toxic solvent residues.
Full Text __


FORM 2
THE PATENT ACT 1970
(39 of 1970)
&
The Patents Rules, 2003
COMPLETE SPECIFICATION
(See section 10 and rulel3)







1. TITLE OF THE INVENTION:
"Novel herbal compositions and process for preparation thereof
2. APPLICANT
(a) NAME: Nisarga Biotech Pvt. Ltd.
(b) NATIONALITY: Indian Company incorporated under the Indian
Companies ACT, 1956
(c) ADDRESS: 275 Chandan Nagar, Addl. M.I.D.C., Satara -415004,
Maharashtra India
3.PREAMBLE TO THE DESCRIPTION
The following specification particularly describes the invention and the manner in which it is to be performed.

Technical field:
The present invention relates to processes for potentiating therapeutic powder of herb/herbs by adding beneficial extractives either individually or in combination containing all the temperature sensitive lypophylic active ingredients and slightly polar and water soluble extractives thereof and which are free from toxic solvent residues. The present invention further relates to novel compositions comprising the potentiated therapeutic powder of herb/herbs comprising beneficial extractives of herb / herbs and raw powder of herb/ herbs which obviate the need of inactive carrier. The present invention further relates to a process of extracting and combining beneficial extractives from the selected herbs comprising all the temperature sensitive lypophylic active ingredients and slightly polar and water soluble extractives which are free from toxic solvent residues.
Background of the Invention:
There are several known herbs in India, which are used traditionally in herbal formulations. The present way of using such herbs in various formulations can be broadly classified as under
i) Use of herbs freshly harvested to make decoctions or fresh juice and formulating the same in various combinations as defined in the Ayurvedic texts.
ii) Use of herbs or parts of herbs after harvesting/drying under shed and powdering such herbs or parts of herbs and mixing such herbs together in the form of powder and using the same for the health care applications (either as a preventive, curative or supportive to human or animal health as supplementary or therapeutic).
The administering the mixture of dried herb powders, in required dosages for getting the full benefit of the therapeutic properties of the herbs is very difficult due to high daily dosage requirement. Hence, several better method of making herbal formulations have tried to improve the dosage as described below.
2

iii) First such improvement is by making "Extracts" of such powders from concentrates of such herbs made in water and using all the extractive of such herbs for beneficial applications in herbal health care and herbal dietary supplements in various forms like powders, capsules, tablets etc.
Here, it has been observed in many scientific evaluations, that in spite of improving the dosage of "water soluble" or only "Highly Polar" ingredients, the formulations did not offer remarkable benefit of the equivalent dosage of herbal powders or mixtures of the herbal powders. The probable reason is the herbs are consisting of several "Highly Polar" (water soluble), "Slightly polar" (soluble in alcohol) and "Non Polar" (lypophylic) constituents, which act either individually or collectively in a synergistic manner. How and why this happens is still largely unknown to the scientific community. So selective use of "Water Soluble" or only "Polar" ingredients do not give the comparable benefits of equivalent dosage of herb powders reported in the earlier evaluations.
iv) These shortcomings were improved by US Patent No.5494668. As described therein, the polar solvents were used initially for extraction and then subjected the residue to extraction using several hydrocarbon or petroleum solvents such as Hexane, Methanol, Petether, Acetone etc. Further such extractives made, using polar solvent (Water) and hydrocarbon solvents (petroleum solvents, which are slightly polar and non polar in nature) were combined together to form the "beneficial extracts" for using them together and mixing such "beneficial" extracts from various herbs together and mixing it with inert pharmaceutical carriers like Dicalcium phosphate (DCP) to offer in convenient dosage and form for use in various health care applications in capsules or tablet forms.
This method of making a combination of "Polar" and "Non Polar" beneficial extractives has following known shortcomings.
a) While subjecting the herb(s) or part of herb(s) to water extraction (for getting the "polar" beneficial extracts), the herb powder gets exposed to high temperatures. This destroys many heat sensitive elements in the
3

process. In many cases, the composition of some natural molecules in the herbs changes dramatically due to hydrolysis. For example, when Clove bud is subjected to heat, the eugenol acetate is converted in eugenol or when Sandalwood powder is subjected to heat the santelyl acetate is converted into santalol because of hydrolysis. Many such minor heat sensitive ingredients are either completely destroyed or change the form thereby reducing the beneficial therapeutic effects of the herbs.
Another major shortcoming is use of hydrocarbon petroleum solvents for extracting the herb powders / residues of herb powders after removing the polar (water soluble) extractives from the herb. The extracts obtained using such solvents like methanol, hexane, petroleum ether, acetone, toluene etc. are found to contain residues of such solvents. The residues of solvent even at ppm levels, administered orally to animals / humans are potential carcinogens or toxins.
The extraction carried out using such solvents, also has one more serious shortcoming. The temperature at the time of separation of extractives from the solvents is always more than the extraction temperature. This means that the extractives are subjected to higher temperature at the time of separation. This destroys many temperature sensitive ingredients present in the extract. The solvents also some times react with the constituents and change the form of many ingredients.
The idea of using such extractives together along with pharmaceutical carriers like DCP (Di Calcium Phosphate) or Malto Dextrin means administration of non-therapeutically beneficial ingredients to the object (animal/human). This defeats the purpose of administering the maximum therapeutically beneficial ingredients to the object. Due to this excess load on the body/system of the object of "non beneficial", "non-absorbable" matter having no pharmacological/biochemical activity, results in lowering the efficacy of the formulations.
4

These shortcomings are eliminated by supercritical fluid extraction method which are reported in WO0072861, US6761913, US6576274, US6352728, US 200212710 and US 20020197341, etc.
WO0072861 describes methods of extracting and purifying bioactive substances from various plants and herbs, such as Kava root, Byrsonima species, Aesculus californica, Crataegus mexicana, Simmondsia chinensis, Pfaffia species, Alternanthera repens, Bursera species, Turnera species, Perezia species, Heimia salicifolia, Psidium species, Enterlobium species, Ptychopetalum olacoides, Liriosma ovata, and Chaunochiton kappleri, using supercritical fluid extraction and/or fluorocarbon solvent extract. These extracts are further used in formulation.
US 6,761,913 describes the compositions and methods for the prevention and treatment of pain, inflammation and gastrointestinal irritation. The compositions comprise a purified, biologically active extract of celery seed, and may further be co-formulated with an additional analgesic or anti-inflammatory compound. The biologically active extract of celery seed is prepared by supercritical fluid extraction. An alcoholic extract of fresh celery seed is mixed with a suitable adsorbant, and then subjected to supercritical fluid extraction. Optionally, the resulting product is further treated or fractionated.
US 200212710 and US 20020197341 describe physiologically synergistic mixtures of pomegranate extracts along with pomegranate seed oil and methods of use thereof. The pomegranate extract was prepared by supercritical fluid extraction.
There is no prior art which reports method of potentiating the therapeutic herb / herbs powder by using beneficial extractives prepared by supercritical fluid extraction and further use in health care formulation.
Objectives of the invention:
The main objective of the present invention is to provide a sustainable, ecologically beneficial method of potentiating the therapeutic herb/herbs powder and using them in healthcare formulations, with "beneficial extractives either individually or in
5

combinations" containing all the temperature sensitive lypophylic active ingredients, slightly polar and water soluble extractives, which are free from toxic solvent residues.
Summary of the invention
According to the present invention, there is provided a method for potentiation of powder of herb / herbs by adding beneficial extractives either individually or in combination containing all the temperature sensitive lypophylic active ingredients which are free from toxic solvent residues and slightly polar(alcohol soluble) and polar water soluble extractives and a method for using the potentiated therapeutic powder of herb / herbs, in health care applications.
A method of potentiating the therapeutic powder of herb / herbs by adding beneficial extractives either individually or in combination comprising cleaning and shed drying the selected raw herb(s) for a particular health benefit; pulverizing it into powder form; mixing the extracts C and W of the herb/herbs in different proportion described in the following examples to potentiate the selected raw herb / herbs powder made as described above along with Aerated silica to make a homogeneous highly potentiated herb powder(s) mixture in a free flowing homogeneous powder form; formulating the free flowing homogeneous potentiated herb powder/ combination of powders in tablets, capsules (Gelatin) or capsules (Vegetarian), which is a convenient form for use in health care applications.
According to the present invention, there is provided potentiated powder of herb / herbs by adding beneficial extractives either individually or in combination containing all the temperature sensitive lypophylic active ingredients which are free from toxic solvent residues and slightly polar(alcohol soluble) and polar water soluble extractives
The present invention further discloses novel compositions comprising the potentiated therapeutic powder of herb / herbs comprising beneficial extractives either individually or in combinations.
6

According to the present invention, there is provided a process of extracting beneficial extractives from the selected herbs preferably comprising all the temperature sensitive lypophylic active ingredients which are free from toxic solvent residues and slightly polar and water soluble extractives.
According to the present invention, a process of extracting beneficial extractives from the selected herbs preferably comprising all the temperature sensitive lypophylic active ingredients comprises cleaning the herb/herbs and powdering the herb/herbs; subjecting the herb / herbs to supercritical C02 extraction to obtain the extract containing all temperature sensitive lypophilic (non polar) ingredients (Extract A) soluble in supercritical C02; subjecting the residual herb after the supercritical supercritical C02 extraction to extraction using supercritical C02 and ethyl alcohol as a co-solvent and obtaining an extract containing alcohol soluble (slightly polar) beneficial ingredients (Extract B); combining extract A and B to get Extract C; and subjecting the residual herb / herbs obtained after getting extract B to water extraction and obtaining the extract in powder form containing polar ingredients (Extract W).
Description of drawings:
Fig 1 shows the HPLC profiles of "Extract C" of Neem Leaves having more number
and more intense peaks of semi polar and non-polar bioactive constituents
compared to water extract. Fig 2 shows HPLC profile of Water Extract of Neem Leaves having more intense
peaks of polar active ingredients indicating higher concentration of polar active
ingredients and absence of non-polar bioactive constituents. Fig 3 shows HPLC profiles of "Extract C" of Bacopa monniera having more number
and more intense peaks of semi polar and non-polar bioactive constituents as
compare to water extract. Fig 4 shows HPLC profile of Water Extract of Bacopa monniera having more intense
peaks of polar active ingredients indicating higher concentration of polar active
ingredients and absence of non-polar bioactive constituents. Fig 5 shows the HPLC profiles of "Extract C" of Ashwagandha Roots having more
number and more intense peaks of semi polar and non-polar bioactive constituents
compared to water extract.
7

Fig 6 shows HPLC profile of Water Extract of Ashwagandha Roots having more intense peaks of polar active ingredients indicating higher concentration of polar active ingredients and absence of non-polar bioactive constituents.
Fig 7 shows Organoleptic profile of the total beneficial extracts as described in the description (combination of "Extract C and W")
Detailed description
According to one aspect of the present invention, there is provided potentiated therapeutic powder of herb / herbs by adding beneficial extractives from the selected herbs preferably comprising all the temperature sensitive lypophylic active ingredients which are free from toxic solvent residues and slightly polar alcohol soluble extractives and water soluble extractives.
According to another aspect of the present invention, there is provided a method for potentiating the therapeutic powder of herb/herbs by adding beneficial extractives either individually or in combination containing all the temperature sensitive lypophylic active ingredients which are free from toxic solvent residues and slightly polar and water soluble extractives and using the same in healthcare applications.
According to yet another aspect of the present invention, there is provided novel compositions comprising the potentiated therapeutic powder of herb / herbs comprising beneficial extractives either individually or in combinations.
According to yet another aspect of the present invention, there is provided a process of extracting beneficial extractives from the selected herbs preferably comprising all the temperature sensitive lypophylic active ingredients which are free from toxic solvent residues and slightly polar and water soluble extractives.
The term "herb" used in the present invention here is intended to cover one or more than one herb depending upon the final health care application.
According to the present invention, a process for preparing novel herbal compositions comprises the following steps :
8

I. A process of extracting beneficial extractives from the selected herb / herbs comprising
1. Cleaning the herb / herbs and powdering the herb / herbs: The herb or part of herb was dried under the shed after removing the external impurities. Such dried herb was powdered in particle size ranging between 0.001 to 4 mm. It was ensured that the powder contains moisture less than 12%. Such powdered herb was then subjected to Supercritical CO2 extraction.
2. Subjecting the herb / herbs to supercritical C02 extraction at a pressure varying between 80 Bar (80 kg/cm2) and 300 Bar (300 kg/cm2) at a temperature ranging between 31° C and 45° C. The CO2 was passed through the herb for a period of 2-3 hours depending upon the size of the extractors and the quantity of herb loaded into the extractor at a time. The quantity of CO2 to be pumped through the herb varies between 10 kg of CO2 / kg of herb to 40 kg of CO2 / kg of herb depending upon the solubility of lypophylic compounds present in the herb. The CO2 carried the extractives to the separator where the pressure of CO2 was reduced to pressure varying between 40 Bar to 65 Bar and temperature between 10° C to 30° C as required to separate the solute (extract) and the CO2.
This method of extraction known as Supercritical CO2 extraction is the safest method of extraction for dried herbs. The extract thus obtained contains all the temperature sensitive minor ingredients present in the herb and also all the other lypophylic soluble compounds. This extract obtained is Extract A.
3. Subjecting the residual herb powders after getting Extract 'A' to extraction
using mixture of CO2 and ethyl alcohol in proportion of 90 to 97%
Supercritical CO2 and 3 to 10% of ethyl alcohol. The extraction was carried
out at the pressure ranging between 80 Bar and 300 Bar and temperature
ranging between 31°C to 45° C. The quantity of solvent pumped (CO2 +
Ethanol) varies between 5 kg/kg of herbs to 40 kg/kg of herbs. The solute
(extract) and ethanol were separated from the CO2 on reducing the solvent
pressure between 40 Bar and 65 Bar and temperature between 10°C to 30°C.
The ethyl alcohol laced with extract was collected from the separator. The
mixture was then subjected to vacuum distillation for separating the ethyl
alcohol completely from the solute (extract), which was Extract B.
9

4. Combining the extract 'A' and extract 'B' to obtain Extract C. This combined extract is also termed as SC02 extract, in the following examples.
5. Subjecting the herb powder residue remainder from above extraction to water extraction to obtain the water-soluble extractives in a paste form. The extract obtained was dried in tray dryers/vacuum dryer or in spray drier to obtain free flowing powder extract. This is Extract W.
The above extraction method was applied on several herbs and the extracts C (Supercritical C02 extracts combined with extracts obtained by Supercritical C02 with Ethyl alcohol as co-solvent) was in liquid/viscous/paste form. The post supercritical water extract (Extract W) was also obtained from the same herbs. This was in a powder form.
According to the present invention, the process of extraction has following important benefits:
1. The combined extracts thus obtained contain all the temperature sensitive minor ingredients present in the herb/herbs, which can contribute to the therapeutic benefit of the herb/herbs.
2. The extracts do not contain any harmful solvent residues/carcinogens/ toxins.
3. The extracts are more "wholistic" or "total" in terms of beneficial ingredients.
The organoleptic profile of the total beneficial extracts as described in the description is explained in fig 5.
These solvent free extracts were combined together and used for potentiation of herbs which was used in health care applications.
Whole herb powders were used in therapeutic applications giving unique advantage of synergistic actions of many known/unknown ingredients in the herb, which may or may not be present in the selective "extracts" obtained from the herb. It is therefore
10

very much beneficial to use "potentiated" herbal powder with such known "beneficial" extractives.
It is an accepted fact that many crops like Wheat, Rice, and Potatoes etc are successfully modified using Genetic modification (GM) technology for increasing the amount of "beneficial" nutrients in the produce. After several years of use, this approach, however, is being questioned as to whether the Genetic modification is safe or whether it will have long- term harmful effects.
According to the present invention, the method adopted for potentiating the herbs involves a physical process of extraction to get the "beneficial" extractives with a very similar organoleptic profile of the herbs without having any harmful solvent residues, which avoids need of genetic modification and use such extractives for potentiation of raw herb powders.
II A method for potentiating therapeutic powder of herb / herbs by adding beneficial extractives either individually or in combination comprising selecting herb / herbs or part thereof to be used for its known health benefit and cleaning from extraneous impurities after drying the same under shed; powdering the herb; sieving the powder to get the raw herb powder of fineness between 0.01 to 1.5 mm and adding beneficial extractives either individually or in combination containing all the temperature sensitive lypophylic active ingredients which are free from toxic solvent residues and slightly polar and water soluble extractives to the raw herb powder.
Different such raw herb powders were used for different health benefits as described in the examples 1 to 15. This raw herb powder(s) were potentiated as described below.
The extractives (Extract C & Extract W) obtained from various herbs were mixed together and then mixed with specific herb / herbs powder of fineness ranging between 0.01 mm and 1.5 mm prepared as described above, along with aerated silica to make a free flowing powder.
11

A combination of at least two extractives of herbs (which are "most beneficial" extractives or herb in terms of pharmacological and biochemical activities) were mixed with at least one raw herb powder from the selected herbs for specific benefits to potentiate the therapeutic powder of herb.
Ill Formulating the free flowing homogeneous potentiated powder of herb / herbs in tablets, capsules (gelatin) or capsules (Vegetarian), which is a convenient form for use in health care applications.
According to the present invention, the composition comprises a combination of at least two extractives of herbs (which are "most beneficial" extractives or herb in terms of pharmacological and biochemical activities) mixed with at least one raw herb powder from the selected herbs for specific benefits.
The main feature of the present invention is to administer "potentiated" herb powder having known benefit and "beneficial" extractives of the supporting herbs together to achieve better therapeutic effect.
Another important feature of the present invention is the use of raw powder of herb / herbs in the compositions thereby obviating the need of inactive carrier.
The raw herb powder (in which extracts were mixed together) was used instead of using any inert carrier like DCP or Malto Dextrin in the composition.
According to the present invention, the lypophylic non-polar extractives and slightly polar alcohol soluble extractives which are in liquid or paste form and polar extractives, which are in powder form, were combined together and were converted in to a uniform matrix.
According to the present invention, the raw herb powder used to improve therapeutic activity of the formulation, as it contain all the ingredients present in the herb, some of which may not be available to the body from the extracts which are likely to be contributing to the therapeutic benefits of the herbs.
12

According to the present invention, the use of such potentiated herb matrix eliminates the necessity of using inert carriers such as DCP/Malto Dextrin, which are useless in terms of therapeutic benefits. Our method will definitely offer a more beneficial effect of the herb powder(s).
According to the present invention, the extracts of different physical nature, (i.e. Extract C in liquid or paste form and Extract W in free flowing powder form) were combined and obtained a free flowing mixture; Aerated silica was used as a drying agent, which also is known to offer certain health benefits.
Advantages of the present invention
1. Retention of heat sensitive elements in extracts, for potentiating the herb(s) powder(s).
2. Elimination of harmful solvent residues from the pharmacologically beneficial extractives.
3. Elimination of "Non beneficial" inert carriers from the formulations.

4 Potentiation of herb powders without making any Genetic modification, so completely ecofriendly way of potentiation of herbs.
5 Aerated Silica used for combining the ingredients also offers health benefits making all the ingredients in the formulation "beneficial" for health care applications.
These novel compositions can be used for health care applications for all animals as well as human.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be
13

resorted to by those skilled in the art, and that such modifications and variations are considered to be falling within the scope of the invention.
The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the invention.
Example 1
Composition containing potentiated powder of Ashwgandha (Withania somnifera) and Shatavari (Asparagus racemosus) for energizing and relieving stress.
Ashwagandha root powder 25 to 100 mg and Shatavari root powder 25 to 80 mg were potentiated with Ashwagandha root SCO2 extract 5 to 25 mg (Extract C) and Ashwagandha root post supercritical hydro extract 80 to 200 mg (Extract W) with Shatavari root SCO2 extract 1 to 10 mg (Extract C), and Shatavari root post-supercritical hydrophilic extract 100 to 480 mg (Extract W). In order to make this mixture free flowing, aerated silica 10 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, Hard gelatin capsules or Veggie capsules 250 to 900 mgs each. This unique mixture of know adoptogens helps in enhancing energy levels while helping to alleviate fatigue. It promotes physical and mental health and helps to support the body's immune defenses and enhances longevity and helps building vitality when administered orally in desired dosages.
Example 2
Composition containing a mixture of potentiated powders of Basil Leaf (Ocimum sanctum) & Turmeric (Curcuma longa) cooked rhizome for supporting upper respiratory functions
Basil whole herb powder 55 to 190 mg and Turmeric rhizome powder 20 to 180 mg were potentiated with Basil leaf C02 extract 10 to 40 mg (Extract C), Basil leaf post supercritical extract 70 to 180 mg (Extract W), Turmeric rhizome SC02 extract 35 to 90 mg (Extract C), Neem leaf (Azadirachta indica) SC02 extract 2 to 17 mgs (Extract
14

C), Long pepper (Piper longum) fruit SC02 extract 2 to 22 mg (Extract C) and Long pepper post supercritical hydro extract 33 to 100 mgs (Extract W). In order to make this mixture free flowing, Aerated silica 10 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 250 to 900 mg each. This mixture helps to elevate body defense against infections, to promote immunity and respiratory health, gives soothing effect to upper respiratory tract when administered orally in desired dosages.
Example 3
Composition containing potentiated powder of Turmeric (Curcuma longa) rhizome as anti-inflammatory agent and blood purifier.
Turmeric rhizome powder 150 to 600 mgs was potentiated with Turmeric rhizome SC02 extracts 40 to 110 mg (Extract C). In order to make this mixture free flowing, Aerated silica 30 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 250 to 820 mgs each. This mixture supports skin, health and luster, acts as blood purifier, helps to reduce inflammation, supports cardiovascular functions when administered orally in desired dosages.
Example 4
Composition containing potentiated powder of Tinospora cardifolia as immuno modulator & hepato protective agent.
Tinospora cardifolia stem powder 100 to 400 mg was potentiated with Tinospora cardifolia root SC02 extract 25 to 80 mg (Extract C), Tinospora cardifolia post supercritical hydro extract 90 to 330 mg (Extract W). In order to make this mixture free flowing, Aerated silica 10 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 250 to 900 mg each. This mixture helps to regulate liver functions, improves immune system and body resistance against infections, promotes longevity when administered orally in desired dosages.
15

Example 5
Composition containing a mixture of Potentiated Brahmi (Bacopa monnieri) powder for imparting calm sleep and helping neuro functions.
Brahmi whole herb powder 100 to 280 mg was potentiated with Brahmi leaves SC02 extract 10 to 45 mg (Extract C), Brahmi leaves post supercritical hydrophilic extract 115 to 450 mg of (Extract W), Spikenard (Nardostachys jatamansi) SC02 extract 2 to 30 mg (Extract C). In order to make this mixture free flowing, Aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 250 to 900 mg each. This unique mixture helps to reduce stress and anxiety, helps improve memory and focus, helps imparting restful calm sleep, and helps improve intelligence and other brain functions when administered orally in desired dosages.
Example 6
Composition containing a mixture of potentiated Pomegranate (Punica granatum) seed and Licorice (Glycyrrhiza glabra) powder for helping female patients suffering from Peri Menopausal syndromes
Pomegranate seed powder 20 to 100 mg and Licorice powder 60 to 100 mg were potentiated with Pomegranate seed SC02 extract 20 to 65 mg (Extract C), Pomegranate post supercritical hydro extract 30 to 260 mg (Extract W), Licorice root SC02 extract 4 to 20 mg (Extract C), Licorice root post supercritical hydrophilic extract 30 to 150 mg (Extract W), Ashwagandha root (Withania somnifera) SC02 extract 3 to 28 mg (Extract C), Ashwagandha root post supercritical hydrophilic extract 70 to 170 mg (Extract W), Tribulus terestris root SC02 extract 20 to 60 mg (Extract C) and Tribulus terestris root post supercritical hydro extract 30 to 90 mg (Extract W). In order to make this mixture free flowing, Aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 250 to 900 mg each. This unique mixture helps to minimize discomfort associated with PMS, helps to improve hormonal
16

imbalance, helps to increase energy and vitality when administered orally in desired dosages.
Example 7
Composition containing potentiated Eclipta alba powder for migraine. Eclipta alba powder 15 to 70 mg and Emblica powder 20 to 80 mg were potentiated with Eclipta alba root SC02 extract 7 to 33 mg (Extract C), Eclipta alba root post supercritical hydrophilic extract 100 to 280 mg (Extract W), Ginger (Zingiber officinale) rhizomes SC02 extract 3 to 22 mg (Extract C), Emblica SC02 extract 5 to 28 mg (Extract C) and Emblica hydrophilic extract 70 to 400 mg (Extract W). In order to make this mixture free flowing, Aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 250 to 900 mg each. This mixture of herb complex helps to support psychosomatic functions, support gastric and liver functions, reduce physical and mental stress, and neutralize the toxins accumulated in the body, thereby helping the patients suffering from migraine when administered orally in desired dosages.
Example 8
Composition containing potentiated Fenugreek (Trigonella foenum-graecum) powder for curing & supporting cardiovascular conditions.
Defatted Fenugreek seed powder 210 to 500 mg was potentiated with Commiphora mukul SC02 extract 25 to 100 mg (Extract C), Turmeric rhizome (Curcuma longa) SC02 extract 40 to 120 mgs (Extract C), Tinospora cardifolia root SC02 extract 5 to 35 mg (Extract C) and Tinospora cardifolia post- supercritical hydrophilic extract 65 to 115 mg (Extract W). In order to make this mixture free flowing, aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This unique mixture helps to balance body metabolism to support healthy cholesterol levels and to support cardiovascular health when administered orally in desired dosages.
17

Example 9
Composition containing potentiated powder of Shatavari (Asparagus racemosus) for supporting womens health.
Shatavari (Asparagus racemosus) powder 50 to 200 mg was potentiated with Shatavari root SC02 extract 1 to 15 mg (Extract C), Shatavari root post supercritical hydrophilic extract 265 to 460 mg (Extract W), Hemidesmus indicus root SC02 extract 23 to 70 mg (Extract C), Hemidesmus indicus post-supercritical hydro extract 75 to 170 mg (Extract W), Berberies aristata root SC02 extract 7 to 25 mg (Extract C), Berberies aristata post supercritical hydro extract 16 to 47 mg (Extract W) and Long pepper (Piper longum) fruit SC02 extract 1 to 10 mg (Extract C). In order to make this mixture free flowing, aerated silica 15 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This mixture helps to elevate vitality, energy and spirit, supports normal development and health of female reproductive system, this herbs complex will help to support pregnancy and lactation when administered orally in desired dosages.
Example 10
Composition containing mixture of potentiated Turmeric (Curcuma longa) & Ashwagandha (Withania somnifera) supporting cancer therapy & improving quality of life for cancer patients.
Turmeric powder 30 to 200 mg and Ashwagandha root powder 30 to 200 mg were potentiated with Turmeric rhizome SC02 extract 80 to 220 mg (Extract C), Ashwagandha root SC02 extract 1 to 20 mg (Extract C), Ashwagandha root post supercritical hydro extract 80 to 230 mg of (Extract W), Tinospora cardifolia root SC02 extract 5 to 45 mg (Extract C), Tinospora cardifolia post supercritical hydrophilic extract 50 to 260 mg (Extract W), Ginger (Zingiber officinale) rhizomes SC02 extract 8 to 32 mg (Extract C) and Neem leaf (Azadirachta indica) SC02 extract 2 to 15 mg (Extract C). In order to make this mixture free flowing, aerated silica 70 to 190 mg was thoroughly mixed together. This mixture was then used to
18

make either tablets, hard gelatin capsules or Veggie capsules 500 to 900 mgs each. This unique mixture helps to support healthy and normal cell growth, prevent nausea and vomiting associated with cancer treatment. Turmeric and Ginger are known for COX-2 inhibition when administered orally in desired dosages.
Example 11
Composition containing potentiated Ashwagandha (Withania somnifera) & Tinospora cardifolia powder for treating Arthritis
Ashwagandha (Withania somnifera) powder 50 to 200 mg and Tinospora cardifolia powder 50 to 200 mg, Boswellia extract powder 90 to 220 mgs, were potentiated with Ashwagandha (Withania somnifera) root SC02 extract 1 to 12 mg (Extract C), Ashwagandha root post-supercritical hydro extract 60 to 180 mg (Extract W), Tinospora cardifolia root SC02 extract 10 to 38 mg (Extract C), Tinospora cardifolia 110 to 260 mg post-supercritical hydro extract (Extract W), Tribulus terestris root SC02 extract 20 to 60 mg (Extract C), Tribulus terestris root 40 to 120 mg of post-supercritical hydrophilic extract (Extract W), and Ginger (Zingiber officinale) rhizomes SC02 extract 3 to 22 mg (Extract C). In order to make this mixture free flowing, aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This mixture helps to reduce inflammation, promotes healthy joints functions, used as mild analgesic containing herbal anti-aging phyto-nutrients that inactivate free radicals, promotes normal cell thereby improving the quality of life of patients suffering from arthritis when administered orally in desired dosages.
Example 12
Composition containing is mixture of potentiated Coriander (Coriandrum sativum) powder and Turmeric (Curcuma lona) powder to help allergic patients.
Turmeric rhizome powder 90 to 225 mg and Coriander seed powder 170 to 385 mg were potentiated with Turmeric rhizomes SC02 extract 40 to 115 mg (Extract C), Coriander seed SC02 extract 50 to 135 mg (Extract C), Neem leaf (Azadirachta
19

indica) SC02 extract 3 to 20 mg (Extract C) and Black pepper (Piper nigrum) fruit SC02 extract 3 to 22 mg (Extract C). In order to make this mixture free flowing, aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This composition helps to improve energy at cellular levels, prevent infections and act as anti-allergy herbs when administered orally in desired dosages.
Example 13
Composition containing potentiated defatted Fenugreek (Trigonella foenum-graecum) powder and Turmeric (Curcuma longa) powder for supporting patients suffering from Type II diabetes
Defatted Fenugreek powder 250 to 400 mg and Turmeric powder 50 -150 mg were potentiated with Turmeric rhizomes SC02 extract 50 to 120 mg (Extract C), Neem leaf (Azadirachta Incia) SC02 extract 4 to 12 mg (Extract C), Tinospora cardifolia SC02 extract 10 to 30 mg (Extract C), and Tinospora cardifolia post supercritical hydrophilic extract 70 to 180 mg (Extract W). In order to make this mixture free flowing, aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This formulation helps to regulate the blood sugar levels, heart and liver functions and neuro functions, which are under constant stress in case of diabetic patients, when administered orally in desired dosages.
Example 14
Composition containing Turmeric (Curcuma longa) and Tinospora Cardifolia powders for heapto protection.
Turmeric powder 50 to 100 mg and Tinospora cardifolia powder 50 to 200 mg were potentiated with Tinospora cardifolia SC02 extract 4 to 25 mg (Extract C), Tinospora post supercritical hydrophilic extract 50 to 150 mg (Extract W), Turmeric (Curcuma longa) SC02 extracts 25 to 75 mg (Extract C), Eclipta alba SC02 extract 5 to 20 mg (Extract C), and Eclipta alba post supercritical hydrophilic extract 40 to 100 mg
20

(Extract W). In order to make this mixture free flowing, aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This formulation helps to reduce discomfort to those suffering from hepatitis conditions when administered orally in desired dosages.
Example 15
Composition containing potentiated Mucuna pruriens and Ashwagandha (withania somnifera) powder for Men's health.
Ashwagandha powder 50 to 200 mg, Mucuna pruriens powder 50 to 200 mg and saffron powder 3 to 10 mg were potentiated with Ashwagandha root SC02 extract 5 to 20 mg (Extract C), Ashwagandha Post supercritical hydrophilic extract 50 to 150 mg (Extract w), Tribulus terestris SC02 extract 10 to 50 mg (Extract C), Tribulus terestris post supercritical extract 25 to 75 mg (Extract W), Mucuna pruriens SC02 extract 10 to 40 mg, and Talimkhana (Asterocantha longifolia) SC02 extract 5 to 20 mg (Extract C). In order to make this mixture free flowing, aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This helps to improve libido, increase strength and stamina and increases sperm count when administered orally in desired dosages.
Example 16
Composition containing potentiated Terminalia chebula powder for Weight management.
Terminalia chebula powder 50 to 150 mg was potentiated with Terminalia chebula SC02 extract 4 to 20 mg (Extract C), Terminalia chebula post supercritical hydrophilic extract 40 to 100 mg (Extract W), Terminalia bellerica SC02 extract 2 to 10 mg (Extract C), Terminalia bellerica post supercritical hydrophilic extract 10 to 40 mg (Extract W), Vijaysar (asna) SC02 extract 3 to 20 mg (Extract C), Pterocarpus Marsupium post supercritical hydrophilic extract 25 to 75 mg (Extract W), Ginger
21

(Zingiber officinale) SC02 extract 1 to 8 mg (Extract C), Black Pepper (Piper nigrum) SC02 extract 1 to 8 mg (Extract C), Long pepper (Piper longum) SC02 extract 1 to 8 mg (Extract C), Embellica ribes SC02 extract 2 to 20 mg (Extract C), Cyperus rotundus SC02 extract 2 to 20 mg (Extract C), Plumbago Zelanica SC02 extract 2 to 15 mg (Extract C), Plumbago Zelanica post supercritical extract 5 to 25 mg. (Extract W). In order to make this mixture free flowing, aerated silica 20 to 100 mg was thoroughly mixed together. This mixture was then used to make either tablets, hard gelatin capsules or Veggie capsules 200 to 900 mg each. This helps to reduce absorption of fats, enhances fat metabolism, improves lipid profile and helps to reduce body weight when administered orally in desired dosages.
22

We claim,
1. A process for potentiating therapeutic herbal powders for preparation of potent pharmaceutical compositions from one or more herbs by adding beneficial extractives of the said herbs, which retains all the temperature sensitive lypophylic active ingredients, and is made free from toxic solvent residues, wherein said process comprises:
a) Preparing said benficial extrctives from selective herb/herbs by
i) cleaning and drying the said selected raw herbs having therapeutic
benefits;
ii) pulverizing the herbs into powder form having the particle size of
0.001 to 4mm with a moisture content of less than 12%;
iii) subjecting the powdered herb/herbs to super critical (C02)
extraction in the ratio of 10 kg of C02 per kg of herb to
40kg of C02 per kg of herb at a pressure varying between
80 bar and 300 bar at a temperature ranging between 31C
and 45C for a period of 2 to 5 hrs to obtain the extract
wherein all temperature- sensitive and other lipophylic(non
polar) ingredients(extract A)are retained;
iv) subjecting the residual herb powders to supercritical C02
and ethyl alcohol in a proportion of 5 kg to 40 kg of
combined solvents per kg of herb/herbs wherein the the
solvents are employed in a proportion of 90-97% of C02
and 3 to 10% of ethyl alcohol as a co-solvent at a pressure
ranging 80-300 bar at a temperature ranging from 31 to 45
C to obtain an extract containing alcohol soluble (slightly
polar) beneficial ingredients(extract B);
v) combining the Extracts A and B to obtain Extract C;
vi) subjecting the residual herb/herbs to water extraction to obtain the extract in powder form containing the polar ingredients(extract W) and
vii) combining the extracts C and W to achieve the beneficial extracts.
23

b) mixing the said beneficial extractives with raw herb powder having a particle size of 0.01mm to 1.5mm
c) mixing the constituents of step ( b) with a pharmaceutically acceptable drying agent to obtain a pure and potent pharmaceutical composition in the form of a free flowing powder.

2. Potent pharmaceutical compositions of potentiated therapeutic herbal powders as in claim 1, wherein said composition comprises all the temperature sensitive lypophilic active ingredients of the herb/herbs; a drying agent, and raw powder of the specific herb/ herbs, obviating the need to use inactive carriers/fillers.
3. A process as in claim 1 and 2 involving supercritical extraction, for potentiating therapeutic herbal powders from one or more herbs as claimed in claim 1, wherein said drying agent is aerated silica.
4. A potent pharmaceutical composition as in claim 1 and 2 ,for energizing and relieving stress, as further described in example 1, comprising: Ashwagandha root powder 25 to 100 mg
potentiated with Ashwagandha root SC02 extract 5 to 25 mg (Extract C)
Ashwagandha root post- supercritical hydro extract 80 to 200 mg (Extract W)
and Shatavari root powder 25 to 80 mg
potentiated with Shatavari root SC02 extract 1 to 10 mg
Shatavari root post-supercritical hydrophilic extract 100 to 480 mg (Extract
W)
Aerated Silica 10 to 100 mg;
5. A potent pharmaceutical composition as claimed in claim 1 and 2, for
supporting upper respiratory functions, as further described in Example 2
comprising:
Basil whole herb powder 55 to 190 mg;
potentiated with Basil leaf C02 extract 10 to 40 mg (Extract C);
Basil leaf post Supercritical extract 70 to 180 mg (Extract W);
Turmeric rhizome powder 20 to 180 mg
potentiated with Turmeric rhizome SC02 extract 35 to 90 mg (Extract C);
Neem leaf (Azadirachta indica) SC02 extract 2 to 17 mgs (Extract C);
Long pepper (Piper longum) fruit SC02 extract 2 to 22 mg (Extract C)
24

Long pepper post supercritical hydro extract 33 to 100 mgs (Extract W) and Aerated Silica 10 to 100 mg.
6. A potent pharmaceutical composition as in claim 1 and 2 as anti-inflammatory agent and blood purifier as further described in example 3 comprising Turmeric rhizome powder 150 to 600 mgs potentiated with Turmeric rhizome SC02 extracts 40 to 110 mg (Extract C) and Aerated silica 30 to 100 mg.
7. A potent pharmaceutical composition as in claim 1 and 2 as immuno modulator and hepato protective agent as further described in example 4 comprising:
Tinospora cardifolia stem powder 100 to 400 mg
potentiated with Tinospora cardifolia root SC02 extract 25 to 80 mg (Extract C), Tinospora cardifolia post supercritical hydro extract 90 to 330 mg (Extract W) and Aerated Silica 10 to 100 mg.
8. A potent pharmaceutical composition as in claim 1 and 2, for imparting calm
and undisturbed sleep and for helping neuro functions, as further described in
example 5, comprising:
Brahmi (Bacopa monnieri) whole herb powder 100 to 280 mg
potentiated with Brahmi leaves SC02 extract 10 to 45 mg (Extract C),
Brahmi leaves post supercritical hydrophilic extract 115 to 450 mg of
(Extract W),
Spikenard (Nardostachys jatamansi) SC02 extract 2 to 30 mg (Extract C) and
Aerated Silica 20 to 100 mg.
9. A potent pharmaceutical composition as in claim 1 and 2, for helping female
patients suffering from Peri Menopausal syndromes, as further described in
example 6, comprising;
Pomegranate seed powder 20 to 100 mg;
Licorice powder 60 to 100 mg were potentiated with Pomegranate seed SC02
extract 20 to 65 mg (Extract C),
Pomegranate post supercritical hydro extract 30 to 260 mg (Extract W),
Licorice root SC02 extract 4 to 20 mg (Extract C),
Licorice root post supercritical hydrophilic extract 30 to 150 mg (Extract W),
Ashwagandha root (Withania somnifera) SC02 extract 3 to 28 mg (Extract C),
Ashwagandha root post supercritical hydrophilic extract 70 to 170 mg (Extract
W), Tribulus terestris root SC02 extract 20 to 60 mg (Extract C),
25

Tribulus terestris root post supercritical hydro extract 30 to 90 mg (Extract W) and Aerated silica 20-100mg.
10. A potent pharmaceutical composition as in claim 1 and 2 for migraine, as
further described in example 7, comprising
Eclipta alba powder 15 to 70 mg;
Emblica powder 20 to 80 mg ;
potentiated with Eclipta alba root SC02 extract 7 to 33 mg (Extract C),
Eclipta alba root post supercritical hydrophilic extract 100 to 280 mg (Extract
W), Ginger (Zingiber officinale) rhizomes SC02 extract 3 to 22 mg (Extract
C), Emblica SC02 extract 5 to 28 mg (Extract C),
Emblica hydrophilic extract 70 to 400 mg (Extract W) and
Aerated silica 20-100mg.
11. A potent pharmaceutical composition as in claim 1 and 2 for curing and
supporting cardiovascular conditions, as further described in example 8,
comprising:
Defatted Fenugreek seed powder 210 to 500 mg;
potentiated with Commiphora mukul SC02 extract 25 to 100 mg (Extract C),
Turmeric rhizome (Curcuma longa) SC02 extract 40 to 120 mgs (Extract C),
Tinospora cardifolia root SC02 extract 5 to 35 mg (Extract C);
Tinospora cardifolia post- supercritical hydrophilic extract 65 to 115 mg
(Extract W); and Aerated silica 20-1OOmg.
12. A potent pharmaceutical composition as in claim 1 and 2 for supporting
women's health, as further described in example 9, comprising;
Shatavari (Asparagus racemosus) powder 50 to 200 mg; potentiated with Shatavari root SC02 extract 1 to 15 mg (Extract C), Shatavari root post supercritical hydrophilic extract 265 to 460 mg (Extract W), Hemidesmus indicus root SC02 extract 23 to 70 mg (Extract C), Hemidesmus indicus post-supercritical hydro extract 75 to 170 mg (Extract W), Berberies aristata root SC02 extract 7 to 25 mg (Extract C), Berberies aristata post supercritical hydro extract 16 to 47 mg (Extract W) and Long pepper (Piper longum) fruit SC02 extract 1 to 10 mg (Extract C) and Aerated silica 15-100mg.
26

13. A potent pharmaceutical composition as in claim 1 and 2 for supporting
cancer therapy and improving quality of life for cancer patients, as further
described in example 10, comprising;
Turmeric powder 30 to 200 mg; and
Ashwagandha root powder 30 to 200 mg were
potentiated with Turmeric rhizome SC02 extract 80 to 220 mg (Extract C),
Ashwagandha root SC02 extract 1 to 20 mg (Extract C),
Ashwagandha root post supercritical hydro extract 80 to 230 mg of (Extract
W), Tinospora cardifolia root SC02 extract 5 to 45 mg (Extract C),
Tinospora cardifolia post supercritical hydrophilic extract 50 to 260 mg
(Extract W),
Ginger (Zingiber officinale) rhizomes SC02 extract 8 to 32 mg (Extract C),
Neem leaf (Azadirachta indica) SC02 extract 2 to 15 mg (Extract C) and
Aerated silikca 70-190 mg.
14. A potent pharmaceutical composition as in claim 1 and 2 for treating
Arthritis, as further described in example 11, comprising;
Ashwagandha (Withania somnifera) powder 50 to 200 mg;
Tinospora cardifolia powder 50 to 200 mg,
Boswellia extract powder 90 to 220 mgs,
were potentiated with Ashwagandha (Withania somnifera) root SC02 extract
1 to 12 mg (Extract C),
Ashwagandha root post-supercritical hydro extract 60 to 180 mg (Extract W),
Tinospora cardifolia root SC02 extract 10 to 38 mg (Extract C),
Tinospora cardifolia 110 to 260 mg post-supercritical hydro extract (Extract
W), Tribulus terestris root SC02 extract 20 to 60 mg (Extract C),
Tribulus terestris root 40 to 120 mg of post-supercritical hydrophilic extract
(Extract W),
Ginger (Zingiber officinale) rhizomes SC02 extract 3 to 22 mg (Extract C)
and Aerated silica 20-100mg.
15. A potent pharmaceutical composition as in claim 1 and 2 for allergic patients,
as further described in example 12, comprising;
Turmeric rhizome powder 90 to 225 mg and Coriander seed powder 170 to 385 mg
27

potentiated with Turmeric rhizomes SC02 extract 40 to 115 mg (Extract C), Coriander seed SC02 extract 50 to 135 mg (Extract C), Neem leaf (Azadirachta indica) SC02 extract 3 to 20 mg (Extract C); Black pepper (Piper nigrum) fruit SC02 extract 3 to 22 mg (Extract C); and Aerated silica 20-100mg
16. A potent pharmaceutical composition as in claim 1 and 2 for supporting
patients suffering from Type II diabetes, as further described in example 13
comprising;
Defatted Fenugreek powder 250 to 400 mg and Turmeric powder 50 -150 mg potentiated with Turmeric rhizomes SC02 extract 50 to 120 mg (Extract C), Neem leaf (Azadirachta Incia) SC02 extract 4 to 12 mg (Extract C), Tinospora cardifolia SC02 extract 10 to 30 mg (Extract C), Tinospora cardifolia post supercritical hydrophilic extract 70 to 180 mg (Extract W) and Aerated silica 20-100mg.
17. A potent pharmaceutical composition as in claim 1 and 2 useful for hepato
protection, as further described in example 14 comprising;
Turmeric powder 50 to 100 mg and Tinospora cardifolia powder 50 to 200 mg
potentiated with Tinospora cardifolia SC02 extract 4 to 25 mg (Extract C),
Tinospora post supercritical hydrophilic extract 50 to 150 mg (Extract W),
Turmeric (Curcuma longa) SC02 extracts 25 to 75 mg (Extract C),
Eclipta alba SC02 extract 5 to 20 mg (Extract C),
Eclipta alba post supercritical hydrophilic extract 40 to 100 mg (Extract W)
and
Aerated silica 20-100mg.
18. A potent pharmaceutical composition as in claim 1 and 2 for improving men's
health as further described in example 15 comprising;
Ashwagandha powder 50 to 200 mg, Mucuna pruriens powder 50 to 200 mg
and saffron powder 3 to 10 mg
were potentiated with Ashwagandha root SC02 extract 5 to 20 mg (Extract
C), Ashwagandha Post supercritical hydrophilic extract 50 to 150 mg (Extract
w), Tribulus terestris SC02 extract 10 to 50 mg (Extract C),
Tribulus terestris post supercritical extract 25 to 75 mg (Extract W),
Mucuna pruriens SC02 extract 10 to 40 mg,
28

Talimkhana (Asterocantha longifolia) SC02 extract 5 to 20 mg (Extract C)
and
Aerated silica 20-100mg.
19.A potent pharmaceutical composition as in claim 1 and 2 for weight
management, as further described in example 16 comprising;
Terminalia chebula powder 50 to 150 mg
potentiated with Terminalia chebula SC02 extract 4 to 20 mg (Extract C),
Terminalia chebula post supercritical, hydrophilic extract 40 to 100 mg
(Extract W),
Terminalia bellerica SC02 extract 2 to 10 mg (Extract C),
Terminalia bellerica post supercritical hydrophilic extract 10 to 40 mg (Extract
W),
Vijaysar (asna) SC02 extract 3 to 20 mg (Extract C),
Pterocarpus Marsupium post supercritical hydrophilic extract 25 to 75 mg
(Extract W),
Ginger (Zingiber officinale) SC02 extract 1 to 8 mg (Extract C),
Black Pepper (Piper nigrum) SC02 extract 1 to 8 mg (Extract C),
Long pepper (Piper longum) SC02 extract 1 to 8 mg (Extract C),
Embellica ribes SC02 extract 2 to 20 mg (Extract C),
Cyperus rotundus SC02 extract 2 to 20 mg (Extract C),
Plumbago Zelanica SC02 extract 2 to 15 mg (Extract C),
Plumbago Zelanica post supercritical extract 5 to 25 mg. (Extract W) and
Aerated silica 20-100mg.
20. Pharmaceutical dosage forms prepared from potentiated herbal compositions
as in Claims 1 to 19, wherein said dosage form is a tablet.
21. Pharmaceutical dosage forms prepared from potentiated herbal compositions
as in Claims 1 to 19 , wherein said dosage form is a hard gelatin capsule.
22. Pharmaceutical dosage forms prepared from potentiated herbal compositions
as in Claims 1 to 19 , wherein said dosage form is a tablet is a vegetable
capsule in hard or soft gelatine form.
23. Extract C and Extract W of Neem leaves as in Claim 5, 13, and 17,
characterized as in Figure 1 and 2 respectively using HPLC profiles wherein
the Extract C is distinguished to have more number and more intense peaks of
semi polar and non-polar bioactive constituents compared to Extract W and
29

Extract W is distinguished to have more intense peaks of polar active ingredients indicating higher concentration of polar active ingredients compared to Extract C.
24. Extract C and Extract W of Bacopa monnieri as in Claim 8, characterized as in Figure 3 and 4 respectively using HPLC profiles wherein the Extract C is distinguished to have more number and more intense peaks of semi polar and non-polar bioactive constituents compared to Extract W and Extract W is distinguished to have more intense peaks of polar active ingredients indicating higher concentration of polar active ingredients compared to Extract C.
25. Extract C and Extract W of Ashwagandha as in Claim 1,6,10,11 and 15 characterized as in Figure 5 and 6 respectively using HPLC profiles wherein the Extract C is distinguished to have more number and more intense peaks of semi polar and non-polar bioactive constituents compared to Extract W and Extract W is distinguished to have more intense peaks of polar active ingredients indicating higher concentration of polar active ingredients compared to Extract C.
26. Organoleptic profile of Extracts C and Extract W and a combination of Extracts C and W as in Claims 1 to 24 as described in Figure 7.

30

ABSTRACT:
The invention discloses a process of potentiating therapeutic powder of herb/herbs by adding beneficial extractives either individually or in combination containing all the temperature sensitive lypophylic active ingredients thereof and which are free from toxic solvent residues, slightly polar and water-soluble extractives. The invention further discloses novel compositions comprising the potentiated therapeutic powder of herb/herbs comprising beneficial extractives of herb / herbs and raw powder of herb/ herbs thereby obviate the need of inactive carriers. The invention also discloses process of combining beneficial extractives from the selected herbs preferably comprising all the temperature sensitive lypophylic active ingredients, slightly polar and water soluble extractives which are free from toxic solvent residues.
31
- 6 FEB 2006

Documents:

142-mum-2005-abstract (complete).doc

142-mum-2005-abstract (complete).pdf

142-MUM-2005-ABSTRACT(6-2-2006).pdf

142-mum-2005-abstract(granted)-(12-4-2011).pdf

142-mum-2005-cancelled pages(4-3-2011).pdf

142-mum-2005-claims (complete).doc

142-mum-2005-claims (complete).pdf

142-MUM-2005-CLAIMS(29-7-2009).pdf

142-MUM-2005-CLAIMS(AMENDED)-(4-3-2011).pdf

142-mum-2005-claims(granted)-(12-4-2011).pdf

142-MUM-2005-CLAIMS(MARKED COPY)-(4-3-2011).pdf

142-MUM-2005-CLAIMS(RETYPE PAGES)-(29-7-2009).pdf

142-MUM-2005-CORRESPONDEDNCE(25-3-2011).pdf

142-MUM-2005-CORRESPONDENCE(25-3-2011).pdf

142-mum-2005-correspondence(ipo)-(12-4-2011).pdf

142-mum-2005-correspondence-received-06022006.pdf

142-mum-2005-correspondence-received-09032005.pdf

142-mum-2005-correspondence-received.pdf

142-mum-2005-description (complete).pdf

142-mum-2005-description (provisional).pdf

142-mum-2005-description(granted)-(12-4-2011).pdf

142-mum-2005-drawing(granted)-(12-4-2011).pdf

142-mum-2005-drawings.pdf

142-MUM-2005-EXAMINATION REPORT(29-7-2009).pdf

142-mum-2005-form 1(10-3-2005).pdf

142-mum-2005-form 1(29-7-2009).pdf

142-mum-2005-form 18(26-10-2007).pdf

142-mum-2005-form 2(granted)-(12-4-2011).pdf

142-mum-2005-form 2(title page)-(complete)-(6-2-2006).pdf

142-mum-2005-form 2(title page)-(granted)-(12-4-2011).pdf

142-mum-2005-form 2(title page)-(provisional)-(10-2-2005).pdf

142-mum-2005-form 26(10-2-2005).pdf

142-mum-2005-form 3(29-7-2009).pdf

142-mum-2005-form-1.pdf

142-mum-2005-form-2 (complete).doc

142-mum-2005-form-2 (complete).pdf

142-mum-2005-form-2 (provisional).doc

142-mum-2005-form-2 (provisional).pdf

142-mum-2005-form-26.pdf

142-mum-2005-form-3.pdf

142-mum-2005-form-5.pdf

142-MUM-2005-REPLY TO HEARING(4-3-2011).pdf

142-mum-2005-specification(amended)-(29-7-2009).pdf


Patent Number 247505
Indian Patent Application Number 142/MUM/2005
PG Journal Number 15/2011
Publication Date 15-Apr-2011
Grant Date 12-Apr-2011
Date of Filing 10-Feb-2005
Name of Patentee NISARAGA BIOTECH PRIVATE LIMITED
Applicant Address 275 CHANDAN NAGAR, ADDL.M.I.D.C. SATARA-415004
Inventors:
# Inventor's Name Inventor's Address
1 SOMAN, GIRISH SUDHAKAR 465/B5, A/8, PLOT NO.7, BEHIND ABHIMAN PARK, SADAR BAZAR, SATARA-415001
2 PHADKE, SHRIKRISHNA GOVIND 529, PARASNIS COLONY, SATARA-415001
3 BLUM, AUTUMN 5401 23rd AVENUE SOUTH, GULFPORT, FL-33707
PCT International Classification Number A61K35/78
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 NA